

SET to Reduce Multiples Can Be a Tough Sell

BY KATE JOHNSON
Montreal Bureau

NEW ORLEANS — Patients will not accept elective single embryo transfer as a means of reducing the risk of multiple pregnancy unless it offers them an equal chance of conceiving, compared with the transfer of two embryos, Moniek Twisk said at the annual meeting of the American Society for Reproductive Medicine.

"To reduce the risk of multiple pregnancy it is essential to offer SET [single embryo transfer] that does not negatively affect pregnancy rates," said Ms. Twisk, a Ph.D. student at Academic Medical Center in Amsterdam. "It is only such an approach that will not jeopardize patient acceptance of SET."

The study found that even if patients believed their pregnancy chances were the same with either single- or double-embryo transfer, less than half would choose SET.

Her study was a questionnaire-based survey of 244 women undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) at two fertility centers in the Netherlands. The questionnaire presented various trade-offs in which either SET or double-embryo transfer (DET) were proposed, with different pregnancy rates and numbers of cycles required to achieve pregnancy.

Patients, who were a mean age of 34 years, with a mean infertility duration of 4 years, were told to assume a 25% chance of multiple pregnancy with DET, and a 1% chance with SET.

The study found that even if patients believed their pregnancy chances were the same with either SET or DET, less than

half of them would choose SET to reduce the chance of multiple pregnancy. This may be partly due to the fact that, according to other studies, up to 27% of women undergoing IVF say they would actually prefer to have twins rather than a singleton, she commented.

If the patients were told that SET would lower their chances of pregnancy even fewer said they would choose this option. (See sidebar.)

Patients were then asked to consider

their willingness to undergo additional cycles of SET to achieve the same success rate as three cycles of DET (without the risk of multiple pregnancy).

Even if three cycles of SET provided the same success rate as three cycles of DET, less than half said they would choose this option, said Ms. Twisk. If subjects were told that four, five, or six cycles of SET could achieve the same pregnancy rate as DET, even fewer said they would accept this option.

The issue of cost for the extra cycles was not explored in the study, Ms. Twisk said in an interview. In the Netherlands patients are usually reimbursed for the first three cycles of IVF, she said.

The results emphasize "unambiguously the overwhelming dominance of pregnancy as the primary goal of treatment for women undergoing IVF/ICSI, and the absence of willingness to trade off that goal in order to avoid a multiple pregnancy," Ms. Twisk said. ■

SET vs. DET Picks Favor the Latter

Willingness to Consider SET Over DET

- ▶ With identical pregnancy chances, 54% prefer DET.
- ▶ If SET reduces chances by 1%, 60% prefer DET.
- ▶ If SET reduces chances by 3%, 76% prefer DET.
- ▶ If SET reduces chances by 5%, 85% prefer DET.

Willingness to Equalize Pregnancy Chances With Extra SET Cycles

- ▶ If three DET cycles = three SET cycles, 54% prefer DET.
- ▶ If three DET cycles = four SET cycles, 60% prefer DET.
- ▶ If three DET cycles = five SET cycles, 64% prefer DET.
- ▶ If three DET cycles = six SET cycles, 65% prefer DET.

Source: Ms. Twisk

In the treatment of atrophic vaginitis, a chronic condition

**A therapy she can stay with.
VAGIFEM®. What's not to love?**



- It's clean
- It's simple
- It's convenient
- It's effective¹
- It's well tolerated¹

It's easy to see why women stay with VAGIFEM.

FREE VAGIFEM SAMPLES! WHAT'S NOT TO LOVE?

To order VAGIFEM samples, visit www.novomedlink.com or call 1-888-VAGIFEM.



Please see adjacent page for brief summary of prescribing information including boxed warning.

©2006 Novo Nordisk Inc. September 2006 Printed in USA 130858

THERAPY SHE CAN STAY WITH

VAGIFEM[®] 25µg
estradiol vaginal tablets

IMPORTANT SAFETY INFORMATION

ESTROGENS HAVE BEEN REPORTED TO INCREASE THE RISK OF ENDOMETRIAL CARCINOMA.

Three independent, case-controlled studies have reported an increased risk of endometrial cancer in postmenopausal women exposed to exogenous estrogens for more than one year. This risk was independent of the other known risk factors for endometrial cancer. These studies are further supported by the finding that incident rates of endometrial cancer have increased sharply since 1969 in eight different areas of the United States with population-based cancer-reporting systems, an increase which may be related to the rapidly expanding use of estrogens during the last decade.

The three case-controlled studies reported that the risk of endometrial cancer in estrogen users was about 4.5 to 13.9 times greater than in nonusers. The risk appears to depend on both duration of treatment and on estrogen dose. In view of these findings, when estrogens are used for the treatment of menopausal symptoms, the lowest dose that will control symptoms should be utilized and medication should be discontinued as soon as possible. When prolonged treatment is medically indicated, the patient should be reassessed, on at least a semiannual basis, to determine the need for continued therapy.

Close clinical surveillance of all women taking estrogens is important. In all cases of undiagnosed persistent or reoccurring abnormal vaginal bleeding, adequate diagnostic measures should be undertaken to rule out malignancy. There is no evidence at present that "natural" estrogens are more or less hazardous than "synthetic" estrogens at equi-estrogenic doses.

Other warnings include: induction of malignant neoplasms, gallbladder disease, effects similar to those caused by estrogen-progestogen oral contraceptives (such as thromboembolic disease, hepatic adenoma, elevated blood pressure, worsening of glucose tolerance), hypercalcemia, and rarely, trauma induced by the Vagifem[®] applicator.

In a placebo-controlled clinical trial, the most commonly reported adverse events included: headache (9%), abdominal pain (7%), upper respiratory tract infection (5%), genital moniliasis (5%), and back pain (7%).

The use of Vagifem[®] is contraindicated in women who exhibit one or more of the following: known or suspected breast carcinoma, known or suspected estrogen-dependent neoplasia, e.g., endometrial carcinoma, abnormal genital bleeding of unknown etiology, known or suspected pregnancy, porphyria, hypersensitivity to any Vagifem[®] constituents, active thrombophlebitis or thromboembolic disorders, or a past history of thrombophlebitis, thrombosis, or thromboembolic disorders associated with previous estrogen use (except when used in treatment of breast malignancy).